IO Biotech Inc

NASDAQ IOBT

Data sourced from

and

Download Data

IO Biotech Inc Earnings Per Share (EPS), Diluted for the quarter ending March 31, 2024

IO Biotech Inc Earnings Per Share (EPS), Diluted is NA for the quarter ending March 31, 2024. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities.

IO Biotech Inc Earnings Per Share (EPS), Diluted for the quarter ending March 31, 2023 was USD -0.59, a 0.93% change year over year.
IO Biotech Inc Earnings Per Share (EPS), Diluted for the quarter ending March 31, 2022 was USD -0.60, a -23.41% change year over year.
IO Biotech Inc Earnings Per Share (EPS), Diluted for the quarter ending March 31, 2021 was USD -0.48.

NASDAQ: IOBT

IO Biotech Inc

CEO	Dr. Mai-Britt Zocca Ph.D.
IPO Date	Nov. 5, 2021
Location	Denmark
Headquarters	Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees	68
Sector	Healthcare
Industry	Biotechnology

Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Key trends